<DOC>
	<DOC>NCT01294605</DOC>
	<brief_summary>This purpose of the study is to evaluate the immunogenicity and reactogenicity of Boostrix™ (when used in a primary schedule (0, 1, 6-month) or a single dose of Boostrix-IPV followed by two doses of Td vaccines (DitanrixTM Adult, TedivaxTM), as compared to three doses of licensed Td vaccines in adults.</brief_summary>
	<brief_title>Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>Only subjects for whom the investigator believes the requirements of the protocol will be complied with will be enrolled in the study A male or female adult &gt;= 40 years of age Written informed consent to be obtained from the subject prior to study entry No history of diphtheria or tetanus toxoid containing vaccination in the last 20 years, including those who have never been vaccinated and those with an unknown vaccination status. Free of obvious health problems as established by medical history and clinical examination before entering into the study. subject should not be pregnant or plan to become pregnant. Use of any investigational or nonregistered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period Chronic administration of immunosuppressants or other immunemodifying drugs within six months prior to the first vaccine dose. Major congenital defects or serious chronic illness. History of any neurologic disorders or seizures Acute disease at the time of enrolment. Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. Pregnant or lactating female Female planning to become pregnant or planning to discontinue contraceptive precautions Previous vaccination with a meningococcalconjugate vaccine, Prevenar™ or other experimental conjugated pneumococcal vaccines History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s). Any confirmed or suspected immunosuppressive or immunodeficient condition</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>DTPa</keyword>
	<keyword>Td</keyword>
	<keyword>IPV</keyword>
</DOC>